Reviva Pharmaceuticals Holdings, Inc. ( (RVPH) ) has released its Q3 earnings. Here is a breakdown of the information Reviva Pharmaceuticals Holdings, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on developing next-generation therapeutics for central nervous system, inflammatory, and cardiometabolic diseases. The company is known for its innovative drug candidates, including brilaroxazine, which is being developed for schizophrenia and other conditions.
Reviva Pharmaceuticals recently reported its third-quarter financial results for 2025, highlighting significant progress in its clinical programs. The company is preparing for a pre-NDA meeting with the FDA regarding brilaroxazine’s approval for schizophrenia, with a potential NDA submission targeted for the second quarter of 2026. Additionally, Reviva has secured a European patent for brilaroxazine’s use in treating pulmonary fibrosis, further strengthening its global patent portfolio.
Key financial metrics indicate a net loss of approximately $4.0 million for the third quarter of 2025, a significant improvement from the $8.4 million loss in the same period the previous year. The company’s cash and cash equivalents stood at $13.2 million as of September 30, 2025. Reviva also completed a public equity offering, raising $9.0 million in gross proceeds.
Reviva’s clinical advancements include the successful completion of a Phase 3 study evaluating brilaroxazine’s long-term safety and efficacy in schizophrenia patients. The study demonstrated robust efficacy and a favorable safety profile, with no significant side effects reported. The company continues to explore partnership opportunities to expand its pipeline and enhance its market presence.
Looking ahead, Reviva Pharmaceuticals remains focused on advancing its drug candidates through regulatory pathways and exploring strategic partnerships. The management is optimistic about brilaroxazine’s potential to redefine treatment expectations in schizophrenia and improve patient outcomes globally.